Mô tả thực trạng kết quả điều trị fluvoxamin ở người bệnh rối loạn lo âu lan tỏa

0 Người đánh giá. Xếp hạng trung bình 0

Tác giả: Minh Tâm Dương, Thị Phương Thảo Lê

Ngôn ngữ: Vie

Ký hiệu phân loại:

Thông tin xuất bản: Tạp chí Y học Việt Nam 2023

Mô tả vật lý: 301-305

Bộ sưu tập: Metadata

ID: 409175

Thêm vào giỏ Liên kết toàn văn

Tóm tắt
Chủ đề

Mô tả thực trạng kết quả điều trị Fluvoxamin ở người bệnh nội trú rối loạn lo âu lan tỏa tại Viện Sức khỏe Tâm thần. Đối tượng và phương pháp nghiên cứu: tiến hành nghiên cứu ở 62 bệnh nhân rối loạn lo âu lan tỏa theo tiêu chuẩn Phân loại quốc tế bệnh tật - 10, điều trị nội trú tại Viện Sức khỏe Tâm thần Quốc gia, phương pháp nghiên cứu là mô tả cắt ngang, test SF-36, thang CGI. Kết quả: Liều của Fluvoxamin chiếm tỉ lệ cao nhất là 400mg/ngày, thấp nhất 100mg/ngày. Tác dụng phụ hay gặp nhất là khô miệng (chiếm 29,03%), thứ 2 là táo bón và vã mồ hôi. Không có người bệnh nào ghi nhận tác dụng phụ là thay đổi cân nặng và xuất hiện ý tưởng tự sát. Trong quá trình điều trị thì đa số các bệnh nhân được thêm thuốc khác (66,13%), chỉ có 1,61% đối tượng chuyển thuốc. Mô hình kết hợp thuốc thường gặp nhất là giữa Fluvoxamine và benzodiazepine (88,71%), thứ 2 là Fluvoxamin và Quetiapin (59,68%) và thứ 3 là sự kết hợp giữa Fluvoxamine và Sulpirid (29,03%). Kết luận: Sử dụng Fluvoxamine để điều trị rối loạn lo âu lan tỏa nội trú thường được sử dụng với liều cao là 400mg/ngày, ít tác dụng phụ, các tác dụng không mong muốn dễ chấp nhận là khô miệng, táo bón và run. Sự kết hợp điều trị giữa Fluvoxamine và thuốc bình thần (BZD), ATK (Quetiapine, Sulpirid) để đạt thuyên giảm triệu chứng và cải thiện điểm số chất lượng cuộc sống của người bệnh là phổ biến nhất. , Tóm tắt tiếng anh, To describe the current status of fluvoxamine treatment results in inpatients with generalized anxiety disorder (GAD) at the Institute of Mental Health. Subjects and research methods: conducting a study in 62 patients with GAD according to the ICD -10 criteria, inpatient treatment at the Institute of Mental Health. Research methods: Across sectional study, SF-36 test, CGI scale. Results: The highest dose of Fluvoxamine was 400mg/day, the lowest was 100mg/day. The most common side effect is dry mouth (accounting for 29.03%), the second is constipation and sweating. None of the patients reported side effects such as weight change and suicidal ideation. During the course of treatment, most of the patients received other drugs (66.13%), only 1.61% of the subjects switched drugs. The most common pattern of drug combinations was between fluvoxamine and benzodiazepine (88.71%), second was fluvoxamine and quetiapine (59.68%) and third was the combination of fluvoxamine and sulpiride (29.03%). Conclusion: Using Fluvoxamine to treat GAD inpatient is often used with a high dose of 400mg/day, with few side effects, acceptable side effects are dry mouth, constipation and tremor. The most common is the combination of fluvoxamine and tranquilizers (BZD), antipsychotic (Quetiapine, Sulpirid) to achieve symptom remission and improve patients' quality of life scores

Tạo bộ sưu tập với mã QR